Zions Bancorporation, National Association’s Axsome Therapeutics AXSM Stock Holding History

Zions Bancorporation, National Association’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01K	Buy	+6	New	+$1.04K	﹤0.01%	1349

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zions Bancorporation, National Association's AXSM Position: Q1 2026 in Review

Zions Bancorporation, National Association opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 6 shares worth $1.01K. The stake represents ﹤0.01% of the portfolio and ranks #1349 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Zions Bancorporation, National Association held 6 shares of Axsome Therapeutics worth $1.01K as of Q1 2026.
Axsome Therapeutics was a new Zions Bancorporation, National Association position in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q1 2026, its #1349 holding.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q1 2026, filed 8 May 2026.